Annovis Bio, Inc. 8K

Annovis Bio, Inc. announced fiscal 2025 financial results and major clinical, IP, and management updates centered on the development of its lead neurodegenerative disease therapy buntanetap.

On March 16, 2026, Annovis Bio, Inc. reported its fiscal year 2025 financial results and provided comprehensive corporate and clinical updates, highlighting the initiation and progress of a pivotal Phase 3 trial of its lead drug candidate buntanetap in early Alzheimer’s disease, new biomarker data and an open-label extension study in Parkinson’s disease, a positive FDA interaction regarding a planned Parkinson’s disease dementia study, the transition of all company patents to a new, more stable crystal form of buntanetap extending IP protection to 2047, key management appointments including a new CFO and Director of Biostatistics, and year-end financials showing increased R&D spending, a reduced net loss per share, and a cash position of $19.5 million expected to fund operations into the third quarter of 2026.

Filing Facts

CIK

1477845

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-028574

Alert Tier

7